“Tumor Immunology Meets Oncology (TIMO) XIV”, May 24–26th 2018, Halle/Saale, Germany
- 25 Downloads
This article summarizes the highlights of the presentations during the XIVth “Tumor Immunology Meets Oncology” (TIMO) symposium, which was held May 24–26th 2018 at the Martin-Luther-University Halle-Wittenberg in Halle/Saale, Germany. Basic scientists, translational researchers and clinicians provided talks on topics ranged from immune escape mechanisms, immune modulation, composition of the tumor microenvironment and immune metabolism to the design and optimization of immunotherapies.
This meeting attracted again participants from more than ten nations to discuss the major advances in basic tumor immunology and immunotherapies alone or in combination with other regimes thereby building up a close link between pre-clinical and clinical research.
The complex interactions between the immune system and tumor cells led to the identification of a number of molecules that governs these interactions. One major goal of immunotherapeutic strategies is to overcome the mechanisms...
KeywordsTIMO 2018 Immune escape Tumor microenvironment Immunomonitoring immunotherapy Immune signatures
Clear cell renal cell carcinoma
Epstein Barr virus
Egl nine homolog 3
Favorable combined immune signature
Fibroblast growth factor receptor 3
Head and neck squamous cell cancer
Monocarboxylate transporter 4
Nicotinamide adenine dinucleotide
Next generation sequencing
Prolyl hydroxylase 3
Renal cell carcinoma
Solute carrier family 16 member 3
Sentinel lymph node
Small leucine-rich proteoglycan
Stimulator of interferon genes
The Cancer Genome Atlas
Tertiary lymphoid structure
Regulatory T cell
Unfavorable combined immune signature
We would like to thank all speakers for their participation and Maria Heise for excellent secretarial help.
BS wrote the introduction, the first seven talks, the summary and conclusion. AS made notes during the talks at the conference, summarized the talks and wrote the last 11 talks. Both authors corrected and approved the final version of the manuscript.
We express our appreciation to the sponsors of the symposium: AstraZeneca GmbH, Becton Dickinson GmbH, Biodesix, Bristol-Myers Squibb, CDDF (Cancer Drug Development Forum), Celgene GmbH, Cellex PT, City of Halle, Deutsche Forschungsgemeinschaft (DFG; German Research Foundation), Deutsche Gesellschaft für Immunologie (DGfI; German Society for Immunology), Epiontis GmbH, Essen BioScience Ltd, Fluidigm, GEMoaB GmbH, Immudex USA, Jannsen Cilag GmbH, Lipocalyx GmbH, Miltenyi Biotec GmbH, Roche Pharma AG, Sarstedt, Sciomics GmbH, SERVA GmbH, siTOOLs BioTech GmbH, Society for Immunotherapy of Cancer (SITC), Thermo Fisher Scientific, QIAGEN GmbH.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest. Barbara Seliger is the organizer of the conference.